Many important advances in transplantation have been made during the last decade. The introduction of Orthoclone OKT3 into clinical trials and its subsequent approval by the Food and Drug Administration in 1985 for use as an antirejection agent for renal transplantation were landmarks in the field of clinical transplantation of solid organs. In the decade since the approval of OKT3 for clinical use, much has been learned and written about OKT3. OKT3 now is considered a safe and effective agent for prophylaxis and first-line treatment of acute rejection of solid organ allografts. In this article, the development and use of OKT3 over the last 10 years, as well as the present status and future implications of immune therapy with OKT3, are reviewed.
Get full access to this article
View all access options for this article.
References
1.
ThistlewaiteJRHaagBWGaberA. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine. Transplant Proc.1987;19:1901–1904.
2.
KohlerGMilsteinC. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature.1975;256:495–497.
RoittIM. OKT3: Immunology, production, purification and pharmacokinetics. Clin Transplant.1993;7:367–373.
5.
KreisHLegendreCChatenoudL. OKT3 in organ transplantation. Transplant Rev.1991;5:181–189.
6.
Caillat-ZucmanSBlumenfieldNLegendreC. The OKT3 immunosuppressive effect: In situ antigenic modulation of human graft-infiltrating T cells. Transplantation.1990;49:156–160.
7.
CosimiABBurtonRCColvinRB. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation.1981;32:535–539.
8.
Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplant. N Engl J Med.1985;313:337–342.
9.
PonticelliCRivoltaETarantinoA. Clinical experience with OKT3 in renal transplantation. Transplant Proc.1986;18:942–948.
10.
HirschREckhausMAuchinclossHSachsDHBluestoneJA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice: Immunosuppression of transplantation responses. J Immunol.1988;140:3766–3772.
11.
ThistlewaiteJRGaberAOHaagBW. OKT3 treatment of steroid-resistant renal allograft rejection. Transplantation.1987;43:176–184.
12.
NormanDJBarryJMBennettWM. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional antirejection therapy. Am J Kidney Dis.1988;11:90–93.
13.
D'AlessandroAMPirschJDStrattaRJSollingerHWKalayogluM. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation. Transplantation.1989;47:297–300.
14.
HricikDEZarconiJSchulakJA. Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection. Transplantation.1989;47:272–277.
15.
AbramowiczDGoldmanMDe PauwLVanherweghemJLKinnaertPVereerstraetenP. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation—a single-center, prospective, randomized study. Transplantation.1992;54:433–437.
16.
AbramowiczDGoldmanM. OKT3 for induction of immunosuppression in renal transplantation. Clin Transpl.1993;7:382–392.
17.
CeckaJMGjertsonDTerasakiPI. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high risk groups?Transplant Proc.1993;25:548–549.
18.
FungJJMarkusBHGordonRD. Impact of Orthoclone OKT3 on liver transplantation. Transplant Proc.1987;19(suppl 1):37–44.
19.
CosimiABChoSIDelmonicoFLKaplanMMRohrerRJJenkinsRL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation.1987;43:91–95.
20.
ColonnaJOGoldsteinLIBremsJJ. A prospective study on the use of monoclonal anti-T cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg.1987;122:1120–1123.
21.
KremerABBarnesLHirschRLGoldsteinG. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments. Transplant Proc.1987;19(suppl 1):54–57.
22.
SchroederTJFirstMR. Monoclonal antibodies in organ transplantation. Am J Kidney Dis.1994;23:138–147.
23.
WoodRPShawBWWilliamsL. The use of OKT3 rescue therapy after orthotopic liver transplantation: The University of Nebraska Medical Center experience. Transplant Proc.1988;20(suppl):254–259.
24.
GilbertEMDeWittCWEiswirthCCRenlundDGMenloveRL. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med.1987;82:202–206.
25.
Costanzo-NordinMRSilverMAO'ConnellJB. Successful reversal of acute cardiac allograft rejection with OKT3 monoclonal antibody. Circulation.1987;76(suppl V):V71–V80.
26.
MonacoAGoldsteinGBarnesL. Use of OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppression regimens. Transplant Proc.1987;19:28–31.
27.
NormanDJKahanaLStuartFJ. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation.1993;55:44–50.
28.
OpelzG. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation.1995;60:1220–1224.
29.
CosimiAB. Clinical development of Orthoclone OKT3. Transplant Proc.1987;21(suppl 1):7–16.
30.
CosimiAB. OKT3: First-dose safety and success. Nephron.1987;46(1):12–18.
31.
FerranCSheehanKDyM. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody in mice: Further evidence for transient in vivo T cell activation. Eur J Immunol.1990;20:509–515.
32.
RaasveldMHMBemelmanFJSchellekensP. Complement activation during OKT3 treatment: A possible explanation for respiratory side effects. Kidney Int.1993;43:1140–1149.
33.
AbramowiczDSchandeneLGoldmanM. Release of tumor necrosis factor, interleukin-2, and gamma interferon in serum after injection with OKT3 monoclonal antibody in kidney transplant recipients. Transplantation.1989;47:606–608.
34.
ChatenoudLFerranCLegendreC. In vivo cell activation following OKT3 administration: Systemic cytokine release and modulation by corticosteroids. Transplantation.1990;49:697–702.
35.
ParlevleitKJBemelmanFJYongS-L. Toxicity of OKT3 increases with dosage: A controlled study in renal transplant recipients. Transplant Int.1995;8:141–146.
36.
FarrellML. Orthoclone OKT3: A treatment for acute renal allograft rejection. ANNA J.1987;14:373–376.
37.
JeyarajahDRThistlewaiteJR. General aspects of cytokinerelease syndrome: Timing and incidence of symptoms. Transplant Proc.1993;25(suppl 1):16–20.
38.
Costanzo-NordinMR. Cardiopulmonary effects of OKT3: Determinants of hypotension, pulmonary edema, and cardiac dysfunction. Transplant Proc.1993;25(suppl 1):21–24.
39.
ToddPABrogenRN. Muromonab CD3: A review of its pharmacology and therapeutic potential. Drugs.1989;37:871–899.
40.
MoirET. Nursing care of patients receiving Orthoclone OKT3. ANNA J.1989;16:327–328.
41.
SpiekerCZidekWBarenbrockMSprakelBBuchholzBRahnK-H. Cardiovascular side effects after renal allograft rejection therapy with Orthoclone: Prevention with nitrendipine. J Cardiovasc Pharmacol.1991;18(suppl 1):S79–S81.
42.
SpiekerCZidekWBarenbrockMWienekeRBuchholzBRahnKH. Acute hypertension after renal allograft rejection therapy with OKT3 monoclonal antibody. J Int Med Res.1991;19:419–423.
43.
SpiekerCBarenbrockMBuchholzBHeidenreichSZidek. Cardiovascular effects of ATG and OKT3 in renal allograft recipients. Transplant Proc.1992;24:2594–2595.
44.
HallKADoleEJHunterGCZukoskiCFPutnamCW. Hyperpyrexia related ventricular tachycardia during OKT3 induction therapy. Transplantation.1992;54:1112–1113.
45.
RadhakrishnanJCohenDJ. Cytokine-release syndrome: General risk factor modification: Preparation of high-risk patients for use of OKT3. Transplant Proc.1993;25(suppl 1):60–62.
46.
AbramowiczDCrusiauxAGoldmanM. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med.1992;327:736. Letter to the editor.
47.
AbramowiczDPradierODe PauwL. High-dose glucocorticosteroids increase the procoagulant effects of OKT3. Kidney Int.1994;46:1596–1602.
48.
PradierOMarchantAAbramowiczD. Procoagulant effect of OKT3 monoclonal antibody: Involvement of tumor necrosis factor. Kidney Int.1992;42:1124–1129.
49.
AbramowiczDPradierOMarchantA. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet.1992:339:777–778.
ChanGLWeinsteinSSWrightCE. Encephalopathy associated with OKT3 administration: Possible interaction with indomethacin. Transplantation.1991;52:148–150.
52.
ChatenoudLLegendreCFerranCBachJFKreisH. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome—dosage and kinetics prerequisites. Transplantation.1991;51:334–338.
53.
BemelmanFJBuysmannSSurachnoJWilminkJMSchellekensPten BergeRJM. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Kidney Int.1994;46:1674–1679.
54.
BemelmanFJBuysmannSWilminkJM. Effects of divided doses of steroids on side effects, cytokines, and activation of complement and granulocytes, coagulation and fibrinolysis after OKT3. Transplant Proc.1994;26:3096–3097.
55.
FirstMRSchroederTJHariharanSAlexanderJWWeiskittelP. The effect of indomethacin on the febrile response following OKT3 therapy. Transplantation.1992;53:91–94.
56.
ShieldCFKahanaLPirschJ. Use of indomethacin to minimize the adverse reaction associated with OKT3. Transplantation.1992;54:164–165.
57.
GaughnWJFrancosBBDunnSRBurkeJF. A retrospective analysis of the effect of indomethacin on adverse reactions to Orthoclone OKT3 in the therapy of acute renal allograft rejection. Am J Kidney Dis.1994;24:486–490.
58.
Health Care Financing: Research Report, End-Stage Renal Disease.Washington, DC: Department of Health and Human Services; 1992.
59.
HricikDEBartucciMRSellerMC. Outpatient use of OKT3 for treatment of acute renal allograft rejection. Clin Transpl.1990;4:19–22.
60.
Transplant Center Methodist Medical Center, Dallas Nephrology Associates. Use of Orthoclone OKT3 in an Outpatient Setting: A Survey of Seven Transplant Centers.Burlington, Mass: Putnam Associates, Inc; 1995.
61.
ChatenoudL. Humoral immune response against OKT3. Transplant Proc.1993;25(suppl 1):68–73.
62.
CareyGLisiPJSchroederT. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation. Transplantation.1995;60:151–158.
63.
SchroederTJFirstMRPoulettyCHariharanSPoulettyP. Rapid detection of anti-OKT3 antibodies with the Transtat assay. Transplantation.1992;55:297–299.
NormanDJChatenoudLCohenDShieldCFIII. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc.1993;25(suppl 1):89–92.
66.
OhCSStrattaRJFoxBCSollingerHWBelzerFOMakiDG. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation.1988;45:68–73.
67.
JunkerAKChanKWLiremanDS. Epstein-Barr virus infection following OKT3 treatment. Transplantation.1989;47:574–575.
68.
StrattaRJShaeferMSCushingKA. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg.1992;127:55–64.
69.
SinghNDummerJSKusneSMakowkaLStarzlTEHoM. Impact of OKT3 therapy on cytomegalovirus and herpes simplex virus infections after liver transplantation. Transplant Proc.1988;20(suppl):661–662.
70.
PennI. Cancers complicating organ transplantation. N Engl J Med.1988;323:1767–1768.
71.
HoMMillerGAtchisonRW. Epstein-Barr virus infections and DNA hybridization studies in lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis.1985;152:876–886.
72.
TouraineJLDeteixPEl YafiMTraegerJDubernardJMLeFrancoisN. Virus-induced lymphomas in transplant patients under immunosuppressive therapy. Transplant Proc.1987;19:4087–4088.
73.
NalesnikMAJaffeRStarzlTE. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol.1988;133:173–192.
74.
HantoDWBirkenbachMFrizzeraGGail-PeczalskaKJSimmonsRLSchubachWH. Confirmation of the heterogeneity of posttransplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation.1989;47:458–464.
75.
StarzlTEPennIHalgrimsonCG. Immunosuppression and malignant neoplasm. N Engl J Med.1970;283:934.
76.
PennI. Tumors arising in organ transplant recipients. Adv Cancer Res.1978;28:31–61.
77.
WeintraubJWarnkeRA. Lymphoma arising in cardiac allograft recipients: Clinical and histologic features and immunologic phenotype. Transplantation.1982;33:347–351.
78.
TouraineJEl YakiSBosiE. Immunoglobulin abnormality and infectious lymphoproliferative syndrome (ILPS) in cyclosporine-treated transplant patients. Transplant Proc.1983;15:2798–2804.
79.
HantoDWGail-PeczalskaKJFrizzeraG. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg.1983;198:356–369.
RenECChanSH. Possible enhancement of Epstein-Barr virus infections by the use of OKT3 in transplant recipients. Transplantation.1988;45:988–989.
83.
HirschRLLaytonPCBarnesLAKremerABGoldsteinG. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy. Transplant Proc.1987;19(suppl 1):32–36.
84.
MorrisonVADunnDLManivelCGail-PeczalskaKJPetersonBA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med.1994;97:14–24.
85.
ShieldCFNormanDJ. Immunologic monitoring during and after OKT3 therapy. Am J Kidney Dis.1988;11:120–124.
86.
SchroederTFirstMRMansourME. Antimurine antibody formation following OKT3 therapy. Transplantation.1990;49:48–51.
87.
KimballJANormanDJShieldCF. OKT3 antibody response study (OARS): A multicenter comparative study. Transplant Proc.1993;25:558–560.
88.
McDiarmidSVMillisMTerashitaGAmentMEBusuttilRTerasakiP. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients. Transplant Proc.1990;22:1774–1776.
89.
RossiSJSchroederTJSchlueterKTHantoDW. Pharmacokinetics of OKT3 in liver transplant patients during sequential induction and immunosuppression. Clin Pharmacol Ther.1994;55:149.
